Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro

NCT02104440 | Completed Phase 2

• 2 other identifiers: CSM/CIT2013-000534-35
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of the sequential infusion of allogeneic mesenchymal stem cells (MSC), expanded "in vitro" with platelet lysate without addition of animal products in the treatment of patients undergoing allo-HSCT who developed one or more cytopenias.

Conditions

Cytopenia

Keywords

Cytopenia

Outcome Measures

Primary Outcomes (1)

• Adverse effects at the time of infusion and infections after infusion of MSC

  All the adverse effects that may arise and possible toxicities (WHO grade) after infusion of the cells were collected.

  During the period of infusion of the cells into the patient (an average of one hour)

Secondary Outcomes (1)

• Mesenchymal cell efficiency in recovering cytopenia

  Monitoring will be from the last infusion of MSCs to the patient until 90 days after the last administration

Study Arms (1)

Patients with cytopenia after allo-HSCT

EXPERIMENTAL

Patients with cytopenia after allo-HSCT

Biological: Sequential infusion of allogeneic mesenchymal stem cells expanded "in vitro"

Interventions

Sequential infusion of allogeneic mesenchymal stem cells expanded "in vitro" BIOLOGICAL

Patients with cytopenia after allo-HSCT

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with hematologic malignancies who have been subjected to allo-HSCT and that are diagnosed with one or more peripheral cytopenias with complete chimerism in bone marrow (determined by molecular-STR-studies). They may include:
• Patients who have received as a source of cells MO or SP
• Patients who have received cells from a related donor or unrelated HLA-matched
• Patients transplanted with myeloablative or non-myeloablative conditioning
• Adequate cardiac function assessed from a clinical point of view by the researcher, with no history of ischemic heart disease (angina or myocardial infarction) in the previous 6 months.
• Adequate pulmonary function assessed clinically without evidence of severe obstructive or restrictive lung disease.
• Patients between 18 and 70 years
• Signed informed consent

You may not qualify if:

• Patients whose haemopathy has not been controlled by the transplantation or is in progress at the time of treatment.
• Patients who do not have complete chimerism in bone marrow (performed within 28 days prior to baseline by molecular study -STR-).
• Patients with thrombotic microangiopathy.
• Patients with post-transplant cytopenias with toxic origin in relation to antiviral treatment (eg ganciclovir, valganciclovir) without concomitant graft against host disease.
• Patients with bacterial, viral or fungal infection that is not being controlled with proper treatment.
• Patients with a history of ischemic heart disease (angina or myocardial infarction) in the previous 6 months, and those considered by the investigator does not have adequate cardiac function, evaluated from a clinical point of view.
• Patients with poor lung function, evaluated clinically, according to the researcher.
• Patients who, in the opinion of the investigator, are not on a good position to tolerate treatment.
• Patients who do not have the required donor.
• Women pregnant or at risk of pregnancy by contraceptive measures inadequate.
• Patients \<18 or \> 70 years.
• Patients who did not sign the informed consent.

Sponsors & Collaborators

• Red de Terapia Celular: lead
• University of Navarrra Hospital (Clinica Universitaria): collaborator
• Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán: collaborator
• Hospitales Universitarios Virgen del Rocío: collaborator
• Spanish National Health System: collaborator

Study Sites (1)

University Clinical Hospital of Salamanca

Salamanca, Salamanca/Castilla León, 37007, Spain

Location

MeSH Terms

Conditions

Cytopenia

Condition Hierarchy (Ancestors)

Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Fermín Sánchez-Guijo Martín, Ph.D

  University Clinical Hospital of Salamanca

  PRINCIPAL INVESTIGATOR

• José Rifón Roca, Ph.D

  University of Navarrra Hospital (Clinica Universitaria)

  PRINCIPAL INVESTIGATOR

• José A Pérez Simón, Ph.D

  Hospital Virgen del Rocío

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 22, 2014
• First Posted: April 4, 2014
• Study Start: October 1, 2013
• Primary Completion: March 1, 2017
• Study Completion: March 1, 2017
• Last Updated: March 30, 2017

Record last verified: 2017-03

Locations

ES (1)